Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients

  • Sonia Younas HKU-Pasteur Research Pole, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
  • Hamid Mukhtar Institute of Industrial Biotechnology, Government College University Lahore, Lahore, Pakistan
  • Umar Farooq Gohar Institute of Industrial Biotechnology, Government College University Lahore, Lahore, Pakistan
  • Abdullah Alsrhani Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, Saudi Arabia
  • Badr Alzahrani Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, Saudi Arabia
  • Kashaf Junaid Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, Saudi Arabia
  • Muhammad Usman Qamar Department of Microbiology, Faculty of Life Sciences, Government College University Faisalabad, Pakistan
  • Hasan Ejaz Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, Saudi Arabia https://orcid.org/0000-0002-6185-2042
Keywords: Hepatitis C virus, sofosbuvir, daclatasvir, HCV genotypes, direct-acting antiviral drugs, sustained virologic response

Abstract

Introduction: The conventional interferon therapy of hepatitis C virus has been substituted substantially with sofosbuvir and daclatasvir due to constraints in efficacy and tolerability. This study aimed diagnostically to monitor the effectiveness and side effects of direct-acting antivirals in the management of HCV infections.

Methodology: This prospective study was conducted on HCV-infected patients treated with sofosbuvir and daclatasvir. Different serological, biochemical, hematological, and molecular techniques were used for the assessment of patients. Only treatment-naive patients aged ≥ 18 to 75 years received 12 weeks of treatment. The primary endpoint was a sustained virologic response with undetectable HCV RNA in the patients’ serum at the end of the treatment.

Results: We identified 229 cases of confirmed HCV infections by PCR, 94.3% of which had genotype 3. The study population comprised 66% females and 34% males with a median age of 42.2 ± 10.6 SD. Ninety-three percent of the patients accomplished SVR at week 12. The combined therapy of SOF/DAC achieved the highest efficacy rate (92.6%) among the different HCV genotype 3 patients. A statistically significant relationship was observed between low baseline viral load (p < 0.001; 95% CI = 1.2-3.1) and HCV genotype 3 with minor side effects, including lethargy, headache, nausea, insomnia, diarrhea, and fever.

Conclusions: HCV-infected patients can be treated well with an interferon-free SOF/DAC regimen, tolerated with generally mild adverse effects with a higher SVR.

Author Biography

Hasan Ejaz, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, Saudi Arabia

Assistant Professor of Microbiology

Department of Clinical Laboratory Sciences

College of Applied Medical Sciences

Jouf University, Saudi Arabia

Published
2021-10-31
How to Cite
1.
Younas S, Mukhtar H, Gohar UF, Alsrhani A, Alzahrani B, Junaid K, Qamar MU, Ejaz H (2021) Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients. J Infect Dev Ctries 15:1489-1496. doi: 10.3855/jidc.12912
Section
Original Articles